- Previous Close
0.00 - Open
9.75 - Bid 9.36 x 40000
- Ask 12.10 x 40000
- Day's Range
9.75 - 9.75 - 52 Week Range
9.35 - 12.09 - Volume
2,500 - Avg. Volume
64 - Market Cap (intraday)
1.183B - Beta (5Y Monthly) 0.64
- PE Ratio (TTM)
30.59 - EPS (TTM)
0.34 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield 0.64 (6.16%)
- Ex-Dividend Date May 9, 2024
- 1y Target Est
--
BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. It sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was incorrporated in 1990 and is based in Stockholm, Sweden.
www.biogaia.com225
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BIOGY
View More
Performance Overview: BIOGY
Trailing total returns as of 3/18/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOGY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOGY
View MoreValuation Measures
Market Cap
1.18B
Enterprise Value
1.06B
Trailing P/E
30.50
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.54
Price/Book (mrq)
6.23
Enterprise Value/Revenue
7.59
Enterprise Value/EBITDA
20.01
Financial Highlights
Profitability and Income Statement
Profit Margin
24.70%
Return on Assets (ttm)
11.72%
Return on Equity (ttm)
18.72%
Revenue (ttm)
1.42B
Net Income Avi to Common (ttm)
351.39M
Diluted EPS (ttm)
0.34
Balance Sheet and Cash Flow
Total Cash (mrq)
1.22B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
272.37M
Research Analysis: BIOGY
View MoreCompany Insights: BIOGY
BIOGY does not have Company Insights